$FENC
FENNEC PHARMACEUTICALS INC.

2014 Form 10-K Financial Statement

#000114420415020272 Filed on March 31, 2015

View on sec.gov

Income Statement

Concept 2014 2013 Q4 2013
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.520M $330.0K $1.330M
YoY Change 89.47% -41.07% -14.19%
% of Gross Profit
Research & Development $357.0K $90.00K $579.0K
YoY Change -38.34% -83.93% -72.1%
% of Gross Profit
Depreciation & Amortization $0.00 $0.00
YoY Change
% of Gross Profit
Operating Expenses $357.0K $420.0K $579.0K
YoY Change -38.34% -62.5% -72.1%
Operating Profit -$2.877M -$1.931M
YoY Change 48.99% -46.66%
Interest Expense $700.0K $1.530M $0.00
YoY Change -128.39%
% of Operating Profit
Other Income/Expense, Net $701.0K $3.776M
YoY Change -81.44% -344.72%
Pretax Income -$1.327M $1.110M $2.620M
YoY Change -150.65% -117.05% -150.78%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income 0.0% 0.0%
Net Earnings -$2.176M $1.110M $1.845M
YoY Change -217.94% -117.05% -135.74%
Net Earnings / Revenue
Basic Earnings Per Share -$0.22 $0.19
Diluted Earnings Per Share -$0.22 $66.71K $0.17
COMMON SHARES
Basic Shares Outstanding 9.871M shares 25.16M shares 9.719M shares
Diluted Shares Outstanding 9.871M shares 10.57M shares

Balance Sheet

Concept 2014 2013 Q4 2013
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.310M $1.660M $1.660M
YoY Change 39.16% -27.83% -27.83%
Cash & Equivalents $2.310M $1.663M $1.660M
Short-Term Investments
Other Short-Term Assets $70.00K $8.000K $90.00K
YoY Change -22.22% 33.33% 28.57%
Inventory
Prepaid Expenses $81.00K
Receivables
Other Receivables
Total Short-Term Assets $2.370M $1.750M $1.750M
YoY Change 35.43% -26.16% -26.16%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $2.000K $0.00
YoY Change -140.0%
TOTAL ASSETS
Total Short-Term Assets $2.370M $1.750M $1.750M
Total Long-Term Assets $0.00 $2.000K $0.00
Total Assets $2.370M $1.752M $1.750M
YoY Change 35.43% -25.92% -26.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $310.0K $212.0K $210.0K
YoY Change 47.62% -18.15% -19.23%
Accrued Expenses $130.0K $132.0K $130.0K
YoY Change 0.0% -68.79% -69.05%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.760M $3.207M $3.210M
YoY Change -45.17% -56.2% -56.15%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.760M $3.207M $3.210M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.760M $3.207M $3.210M
YoY Change -45.17% -56.2% -56.15%
SHAREHOLDERS EQUITY
Retained Earnings -$108.7M
YoY Change
Common Stock $106.0M
YoY Change 1.59%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $610.0K -$1.455M -$1.460M
YoY Change
Total Liabilities & Shareholders Equity $2.370M $1.752M $1.750M
YoY Change 35.43% -25.92% -26.16%

Cashflow Statement

Concept 2014 2013 Q4 2013
OPERATING ACTIVITIES
Net Income -$2.176M $1.110M $1.845M
YoY Change -217.94% -117.05% -135.74%
Depreciation, Depletion And Amortization $0.00 $0.00
YoY Change
Cash From Operating Activities -$1.699M -$440.0K -$2.210M
YoY Change -23.12% -20.0% -26.19%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $2.182M $1.570M
YoY Change 38.98%
Debt Paid & Issued, Net $0.00
YoY Change
Cash From Financing Activities $2.343M 1.570M $1.570M
YoY Change 49.24%
NET CHANGE
Cash From Operating Activities -$1.699M -440.0K -$2.210M
Cash From Investing Activities $0.00 0.000 $0.00
Cash From Financing Activities $2.343M 1.570M $1.570M
Net Change In Cash $644.0K 1.130M -$640.0K
YoY Change -200.63% -305.45% -78.62%
FREE CASH FLOW
Cash From Operating Activities -$1.699M -$440.0K -$2.210M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$440.0K -$2.210M
YoY Change -20.0% -26.19%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
4201000 shares
CY2014Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
2307000 USD
CY2014Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
1319000 USD
CY2014Q4 us-gaap Fair Value Net Asset Liability
FairValueNetAssetLiability
3626000 USD
CY2013Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-108698000 USD
CY2014 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
355000 USD
CY2014Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.50
CY2014Q4 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
110874000 USD
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9719000 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10593000 shares
CY2014Q4 us-gaap Cash
Cash
100000 USD
CY2014Q4 us-gaap Cash
Cash
53000 CAD
CY2013 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
3777000 USD
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-110874000 USD
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
132000 USD
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1243000 USD
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q4 us-gaap Assets
Assets
2372000 USD
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
613000 USD
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
68656000 USD
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
41588000 USD
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2372000 USD
CY2014Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
2307000 USD
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2307000 USD
CY2014Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
48000 USD
CY2014Q4 us-gaap Other Assets Current
OtherAssetsCurrent
17000 USD
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
308000 USD
CY2014Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1319000 USD
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1759000 USD
CY2014Q4 us-gaap Liabilities
Liabilities
1759000 USD
CY2013 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
597000 USD
CY2014 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
357000 USD
CY2013Q1 adhxf Issue Of Convertible Common Stock As Per Licence Agreement
IssueOfConvertibleCommonStockAsPerLicenceAgreement
13902000 shares
CY2013Q1 adhxf Expired Convertible Common Stock
ExpiredConvertibleCommonStock
21250000 shares
CY2013Q1 adhxf Milestone Payment Fees
MilestonePaymentFees
100000000 USD
CY2013 us-gaap Revenues
Revenues
0 USD
CY2014 us-gaap Revenues
Revenues
0 USD
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1334000 USD
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2520000 USD
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-1931000 USD
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-2877000 USD
CY2013 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-3000 USD
CY2014 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-5000 USD
CY2013 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
0 USD
CY2014 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
349000 USD
CY2013 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
2000 USD
CY2014 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
2000 USD
CY2013 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3776000 USD
CY2014 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
701000 USD
CY2013 us-gaap Net Income Loss
NetIncomeLoss
1845000 USD
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-2176000 USD
CY2013 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.19
CY2014 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
CY2013 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.17
CY2014 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
CY2013 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9719000 shares
CY2014 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9871000 shares
CY2013 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10571000 shares
CY2014 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9871000 shares
CY2013 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
25000 USD
CY2014 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
434000 USD
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
62000 USD
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
627000 USD
CY2013 us-gaap Increase Decrease In Operating Capital
IncreaseDecreaseInOperatingCapital
365000 USD
CY2014 us-gaap Increase Decrease In Operating Capital
IncreaseDecreaseInOperatingCapital
-120000 USD
CY2013 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2210000 USD
CY2014 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1699000 USD
CY2013 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
CY2014 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
CY2014 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2182000 USD
CY2014 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
140000 USD
CY2013 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1570000 USD
CY2014 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2343000 USD
CY2013 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
0 USD
CY2014 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
0 USD
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-640000 USD
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
644000 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2303000 USD
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
-4957000 USD
CY2014 adhxf Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
21000 USD
CY2014 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
140000 USD
CY2014 adhxf Exchange Of Warrants
ExchangeOfWarrants
840000 USD
CY2013 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2650 pure
CY2014 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2650 pure
CY2013 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
230000 USD
CY2014 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-2863000 USD
CY2014 dei Document Type
DocumentType
10-K
CY2014 dei Amendment Flag
AmendmentFlag
false
CY2014 dei Document Period End Date
DocumentPeriodEndDate
2014-12-31
CY2014 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
CY2014 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2014 dei Entity Registrant Name
EntityRegistrantName
FENNEC PHARMACEUTICALS INC.
CY2014 dei Entity Central Index Key
EntityCentralIndexKey
0001211583
CY2014 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2014 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2014 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2014 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2014 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2014Q2 dei Entity Public Float
EntityPublicFloat
21833720 USD
CY2014 dei Trading Symbol
TradingSymbol
ADHXF
CY2015Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10619535 shares
CY2013 us-gaap Income Tax Reconciliation Repatriation Of Foreign Earnings
IncomeTaxReconciliationRepatriationOfForeignEarnings
36000 USD
CY2014 us-gaap Income Tax Reconciliation Repatriation Of Foreign Earnings
IncomeTaxReconciliationRepatriationOfForeignEarnings
13000 USD
CY2013 adhxf Effective Income Tax Rate Reconciliation Effect Of Noncapital Losses Expired
EffectiveIncomeTaxRateReconciliationEffectOfNoncapitalLossesExpired
0 USD
CY2014 adhxf Effective Income Tax Rate Reconciliation Effect Of Noncapital Losses Expired
EffectiveIncomeTaxRateReconciliationEffectOfNoncapitalLossesExpired
3344000 USD
CY2013 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
222000 USD
CY2014 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-13000 USD
CY2013 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2013 adhxf Expected Provision For Recovery Of Income Tax
ExpectedProvisionForRecoveryOfIncomeTax
489000 USD
CY2014 adhxf Expected Provision For Recovery Of Income Tax
ExpectedProvisionForRecoveryOfIncomeTax
-577000 USD
CY2013 adhxf Permanent Difference
PermanentDifference
-977000 USD
CY2014 adhxf Permanent Difference
PermanentDifference
96000 USD
CY2013Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
27170000 USD
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
24307000 USD
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance Current
DeferredTaxAssetsValuationAllowanceCurrent
27170000 USD
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance Current
DeferredTaxAssetsValuationAllowanceCurrent
24307000 USD
CY2013Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2014Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2014 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0 pure
CY2013 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 USD
CY2014 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
21000 USD
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
2620000 USD
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-1327000 USD
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-775000 USD
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-849000 USD
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
1845000 USD
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-2176000 USD
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1072000 shares
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y7M28D
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y
CY2010Q2 adhxf Percentage Of Total Number Of Share Issued And Outstanding
PercentageOfTotalNumberOfShareIssuedAndOutstanding
0.25 pure
CY2013 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
1138000 shares
CY2014 us-gaap Proceeds From Repayments Of Debt
ProceedsFromRepaymentsOfDebt
-349000 USD
CY2014 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
On August 10, 2011, and again on May 28, 2014, the Board of Directors approved a 1-for-18 and a 1-for-3 reverse stock split, or Share Consolidation, respectively, which became effective on August 25, 2011 and September 3, 2014, respectively. The combined 1-for-54 reverse stock split affected all of the Companys common shares, stock options and warrants outstanding at the effective date.

Files In Submission

Name View Source Status
0001144204-15-020272-index-headers.html Edgar Link pending
0001144204-15-020272-index.html Edgar Link pending
0001144204-15-020272.txt Edgar Link pending
0001144204-15-020272-xbrl.zip Edgar Link pending
adhxf-20141231.xml Edgar Link completed
adhxf-20141231.xsd Edgar Link pending
adhxf-20141231_cal.xml Edgar Link unprocessable
adhxf-20141231_def.xml Edgar Link unprocessable
adhxf-20141231_lab.xml Edgar Link unprocessable
adhxf-20141231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tex10-20logo.jpg Edgar Link pending
v404663_10k.htm Edgar Link pending
v404663_ex10-20.htm Edgar Link pending
v404663_ex31-1.htm Edgar Link pending
v404663_ex31-2.htm Edgar Link pending
v404663_ex32-1.htm Edgar Link pending